Healthcare Industry News: oral mucositis
News Release - January 31, 2011
Erchonia Laser May Help Cancer Patients With Radiation TreatmentsMCKINNEY, TX--(Healthcare Sales & Marketing Network) - Erchonia Corporation, the global leader in low level laser healthcare applications, announces the results of a pilot study testing the ability of low level lasers to reduce the negative side-effects of radiation therapy for cancer patients.
Patients who undergo aggressive cancer therapies must also endure a host of painful side-effects, causing many to terminate treatment before completion. The pilot investigation assessed the efficacy of an Erchonia low-level laser device to combat these adverse reactions. All patients who received the laser treatment revealed a significant improvement in the pain, dermatitis (skin irritation), and oral mucositis (mouth sores) caused by their radiation therapy.
Dr. David Bryant, an oncologist at the Via Christi Medical Center in Kansas, performed the study and used the Erchonia low-energy laser device to treat cancer patients who were experiencing a significant amount of pain. After just a few treatments, results were so significant that patients who were ready to abandon the treatment were able to complete their regimen in full.
Dr. Bryant remarks, "The study was designed just to show a reduction in pain, improved treatment retention, and reduction in treatment toxicity. It was simply incredible to see such a significant reduction and have patients actually able to complete the therapy once they were treated with the laser. This is exciting because the resolution of these symptoms really could be the difference between cancer treatment success and failure."
Based on the encouraging results of the pilot study, Erchonia has embarked on a full clinical trial which should conclude in early 2011.
"The goal is to prove to both physicians and patients that there is a safe and effective treatment available to suppress the common but severe adverse events of radiation therapy," says Steve Shanks, president of Erchonia. "We need to give every cancer patient the best possible chance to succeed."
If the clinical trial is successful, Erchonia plans to pursue FDA clearance in 2012.
About Erchonia Corporation
Erchonia is the global leader in cold laser healthcare applications. For 15 years, Erchonia has been conducting research & development with the world's leading physicians to advance the science of low level lasers. Prior to market introduction, all Erchonia lasers are proven to be safe and effective through independent clinical trials. Currently thousands of Erchonia's lasers are used daily to reduce body fat, eliminate pain, accelerate healing, and treat acne. For additional information, visit www.erchonia.com.
Issuer of this News Release is solely responsible for its
Please address inquiries directly to the issuing company.